About Neuroligin-2
Neuroligin-2 (NLGN2) is a protein
from Homo sapiens identified by UniProt accession
Q8NFZ4, 835 residues long.
MolForge cross-references it against 0 known binders and
52 disease associations.
Target properties
| Protein name | Neuroligin-2 |
|---|
| UniProt accession | Q8NFZ4 |
|---|
| Gene | NLGN2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 835 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8NFZ4-F1 | alphafold | PREDICTED | 77.74 | — |
Amino-acid sequence (835 residues)
MWLLALCLVG LAGAQRGGGG PGGGAPGGPG LGLGSLGEER FPVVNTAYGR VRGVRRELNN EILGPVVQFL GVPYATPPLG ARRFQPPEAP ASWPGVRNAT TLPPACPQNL HGALPAIMLP VWFTDNLEAA ATYVQNQSED CLYLNLYVPT EDGPLTKKRD EATLNPPDTD IRDPGKKPVM LFLHGGSYME GTGNMFDGSV LAAYGNVIVA TLNYRLGVLG FLSTGDQAAK GNYGLLDQIQ ALRWLSENIA HFGGDPERIT IFGSGAGASC VNLLILSHHS EGLFQKAIAQ SGTAISSWSV NYQPLKYTRL LAAKVGCDRE DSAEAVECLR RKPSRELVDQ DVQPARYHIA FGPVVDGDVV PDDPEILMQQ GEFLNYDMLI GVNQGEGLKF VEDSAESEDG VSASAFDFTV SNFVDNLYGY PEGKDVLRET IKFMYTDWAD RDNGEMRRKT LLALFTDHQW VAPAVATAKL HADYQSPVYF YTFYHHCQAE GRPEWADAAH GDELPYVFGV PMVGATDLFP CNFSKNDVML SAVVMTYWTN FAKTGDPNQP VPQDTKFIHT KPNRFEEVVW SKFNSKEKQY LHIGLKPRVR DNYRANKVAF WLELVPHLHN LHTELFTTTT RLPPYATRWP PRPPAGAPGT RRPPPPATLP PEPEPEPGPR AYDRFPGDSR DYSTELSVTV AVGASLLFLN ILAFAALYYK RDRRQELRCR RLSPPGGSGS GVPGGGPLLP AAGRELPPEE ELVSLQLKRG GGVGADPAEA LRPACPPDYT LALRRAPDDV PLLAPGALTL LPSGLGPPPP PPPPSLHPFG PFPPPPPTAT SHNNTLPHPH STTRV
Explore Neuroligin-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets